kynurenic acid has been researched along with Cognitive Decline in 6 studies
Kynurenic Acid: A broad-spectrum excitatory amino acid antagonist used as a research tool.
kynurenic acid : A quinolinemonocarboxylic acid that is quinoline-2-carboxylic acid substituted by a hydroxy group at C-4.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 8.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 7.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 7.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 5.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 4.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 3.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Elevated cerebrospinal fluid (CSF) levels of the glia-derived N-methyl-D-aspartic acid receptor antagonist kynurenic acid (KYNA) have consistently been implicated in schizophrenia and bipolar disorder." | 3.83 | A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder. ( Backlund, L; Bergen, SE; Ekman, CJ; Engberg, G; Erhardt, S; Hultman, CM; Kegel, ME; Landén, M; Larsson, M; Lichtenstein, P; Magnusson, PK; Olsson, S; Schalling, M; Sellgren, CM; Sklar, P; Smoller, JW; Sullivan, PF; Svensson, CI; Vawter, MP; Walther-Jallow, L, 2016) |
| "Kynurenic acid (KYNA) is an antagonist to the α-7nACh and NMDA receptors." | 2.58 | Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement. ( Koola, MM, 2018) |
| "Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions." | 1.72 | The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder. ( Giltay, EJ; Hebbrecht, K; Morrens, M; Sabbe, B; van den Ameele, S; van Nuijs, ALN, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hebbrecht, K | 1 |
| Morrens, M | 1 |
| Giltay, EJ | 1 |
| van Nuijs, ALN | 1 |
| Sabbe, B | 1 |
| van den Ameele, S | 1 |
| Anderson, EW | 3 |
| Jin, Y | 3 |
| Shih, A | 3 |
| Arazi, A | 3 |
| Goodwin, S | 3 |
| Roeser, J | 3 |
| Furie, RA | 3 |
| Aranow, C | 3 |
| Volpe, B | 3 |
| Diamond, B | 3 |
| Mackay, M | 3 |
| Koola, MM | 1 |
| Sharma, R | 1 |
| Razdan, K | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Beggiato, S | 1 |
| Notarangelo, FM | 1 |
| Sathyasaikumar, KV | 1 |
| Giorgini, F | 1 |
| Schwarcz, R | 1 |
| Sellgren, CM | 1 |
| Kegel, ME | 1 |
| Bergen, SE | 1 |
| Ekman, CJ | 1 |
| Olsson, S | 1 |
| Larsson, M | 1 |
| Vawter, MP | 1 |
| Backlund, L | 1 |
| Sullivan, PF | 1 |
| Sklar, P | 1 |
| Smoller, JW | 1 |
| Magnusson, PK | 1 |
| Hultman, CM | 1 |
| Walther-Jallow, L | 1 |
| Svensson, CI | 1 |
| Lichtenstein, P | 1 |
| Schalling, M | 1 |
| Engberg, G | 1 |
| Erhardt, S | 1 |
| Landén, M | 1 |
2 reviews available for kynurenic acid and Cognitive Decline
| Article | Year |
|---|---|
Galantamine-Memantine Combination for Cognitive Impairments Due to Electroconvulsive Therapy, Traumatic Brain Injury, and Neurologic and Psychiatric Disorders: Kynurenic Acid and Mismatch Negativity Target Engagement.
Topics: Animals; Cognitive Dysfunction; Drug Therapy, Combination; Electroconvulsive Therapy; Galantamine; H | 2018 |
Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Drug Development; Humans; Kynurenic Acid; Kynuren | 2018 |
4 other studies available for kynurenic acid and Cognitive Decline
| Article | Year |
|---|---|
The Role of Kynurenines in Cognitive Dysfunction in Bipolar Disorder.
Topics: Bipolar Disorder; Cognitive Dysfunction; Humans; Inflammation; Kynurenic Acid; Kynurenine; Tryptopha | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo | 2018 |
A genome-wide association study of kynurenic acid in cerebrospinal fluid: implications for psychosis and cognitive impairment in bipolar disorder.
Topics: Adult; Aged; Bipolar Disorder; Brain; Chromosomes, Human, Pair 1; Cognition Disorders; Cognitive Dys | 2016 |